Breadcrumb
Health Insurance Marketplaces
Any Willing Provider Legislation 07/29/2014 Revised |
AMCP supports the ability of managed care organizations to selectively contract with only those providers necessary to enable the organization to provide patients with adequate access to pharmacy services and quality, cost-effective health care. By selectively contracting with providers, managed care organizations assure that patients can receive the best care, have access to the providers they need and reduce the likelihood that valuable health care resources will be wasted through inappropriate use. Therefore, the Academy opposes legislation that would require managed care organizations to contract with any provider meets the terms and conditions of the organization, whether or not it can be shown that the provider meets the geographic access needs and/or quality standards of the health plan.
(See AMCP Where We Stand Position Statement - Any Willing Provider Legislation) |
Government-Mandated Pharmacy Benefits 02/13/2019 Reapproved |
AMCP supports the right of managed care organizations and their clients to independently make decisions with regard to health benefits that meet the medical needs of specific patient populations while being compassionate, medically sound, timely, and fiscally responsible. Federal and state legislation and regulations should not hinder a health care delivery system's ability to provide customized benefits that assure value and quality patient care for specific patient populations, yet remain affordable.
|
Prescription Drug Coverage 04/12/2021 Revised 03/29/2022 Revised |
AMCP supports the inclusion of prescription drug coverage in all health care benefit programs, including those administered by the government (e.g., Medicare, Medicaid, health insurance exchanges). Access to and proper utilization of a comprehensive prescription drug benefit, have been shown to reduce the severity of and complications arising from many common illnesses. Failure to provide prescription drug coverage can increase the use of more intensive, costly health care services, such as surgery and/or hospitalization. AMCP also supports granting flexibility to managed care organizations to develop clinically sound, evidence-based benefits free from arduous mandates.
|
Co-payment Offset Programs
02/01/2013 Introduced |
AMCP is supportive of programs that help patients afford their prescription drugs. However, some programs can needlessly encourage the use of more expensive brand-name products over their generic counterparts. They can also undermine the formulary development process by encouraging the use of products that have lower cost therapeutic alternatives. Patient safety can also be threatened when prescriptions are frequently transferred between retail pharmacies. Therefore, AMCP is opposed to manufacturer coupon programs that are promotional in nature and are not means-tested.
(See AMCP Where We Stand Position Statement – Co-Payment Offset Program) |
Competitive Marketplace |
AMCP believes that a health care delivery system that is based upon an open and competitive marketplace will provide greater value to patients and payers than a system that is one-size-fits-all and relies on centralized governmental controls and regulatory mandates. Through innovative and integrated strategies that focus on patient education, quality assurance and drug utilization management, managed care pharmacy has been able to deliver a pharmacy benefit that is clinically sound, accessible and affordable. The most appropriate role of the government in the prescription drug marketplace is as a regulator of the market and protector of consumer’s interest and, in the case of public programs, as a financing entity. AMCP will continue to work closely with government officials, agencies and other payers to constantly refine the services and products sought through pharmacy benefits. |
Regulation of the Prescription Drug Benefit
Policy 1402
10/07/2014 Introduced 04/12/2021 Revised |
AMCP recognizes that government should encourage an environment in which managed care pharmacists continue to develop innovative and integrated strategies to manage prescription drug benefits for a given patient population. AMCP supports statutory and regulatory efforts that will continue to enable the ability of managed care pharmacists to consider the range of clinical, legal, quality-of-life, safety, and pharmacoeconomic factors which form the basis for the design and implementation of effective drug benefit strategies and programs. However, the Academy opposes statutory and regulatory proposals that unduly restrict the ability of managed care pharmacists from using proven tools and practices, such as drug utilization review, formulary management, utilization and network management, that are essential for the management of a prescription drug benefit. These types of proposals are objectionable if they go beyond procedural protections and enter an arena traditionally within the purview, expertise and experience of health care professionals. Unnecessary or overly burdensome regulatory restrictions could place patients at risk and increase the cost of health care. The result could compromise the availability and affordability of the prescription drug benefit.
(See AMCP Where We Stand Position Statement – Regulation of the Prescription Drug Benefit) |